bluebird bio Inc has hired apceth Biopharma GmbH to make its candidate ALD cell therapy Lenti-D and its thalassemia treatment LentiGlobin for the European market.
An automated system co-developed with Cook Regenetec offers a more controlled and repeatable method of thawing cell and gene therapies than traditional techniques, says Asymptote.
Selexis and Xencor have entered into a strategic agreement which strengthens an existing relationship for multi-specific antibody cell line development
The cell and gene therapy plant Lonza is building in Pearland, Texas will be bigger than originally planned to according to the city’s economic development corporation.
Germany's Merck says gene editing can make CHO cells resistant to a tiny mouse virus that continues to be a problem for even animal component-free production processes.
Differentiated technologies buoyed by the recent $600m conjugation deal with Roche is driving Catalent’s biologics business, the firm told Biopharma-Reporter at BIO.
The new 50,000 square foot facility in Lexington, MA will be dedicated to late phase development and commercial manufacturing for advanced cell and gene therapies.
LeukoDx will develop a cell characterization system for GE Healthcare in a deal designed to bolster the latter’s cell therapy manufacturing technology offering.
A UK firm has launched a searchable database of genomic data from sources all over the world that it says will accelerate development of personalised medicines.
Aragen Bioscience and Transposagen Biopharmaceuticals have launched a knockout CHO cell line and development services they clam allows for the development of more effective therapeutic mAbs.
Biomay has licensed a yeast-based expression system from fellow Austrian biotech VTU Technologies to use for the commercial production of its recombinant allergens.
Big Pharma is not the only slow moving behemoth involved in the CRISPR/Cas9 revolution with a US team citing the gene editing tech as key to its efforts to resurrect the woolly mammoth.
Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.
CRISPR gene editing will make cell line development cheaper and faster according to Horizon Discovery, which says that new tech has application in both biomanufacturing and preclinical disease modelling.
Miltenyi Biotec has acquired the lentiviral vector manufacturing business and related assets from Lentigen, a lentiviral technology provider for cell and gene therapy applications.
The draft guidance aims to provide sponsors of virus or bacteria-based gene therapy products (VBGT products) and oncolytic viruses or bacteria (oncolytic products) with recommendations on how to conduct shedding studies during preclinical and clinical...
The European Medicines Agency’s Committee for Advanced Therapies (CAT) has revised a reflection paper on the classification of advanced-therapy medicinal products (ATMPs) to reflect cases in which medicines can be classified as ATMPs.
Thermo Fisher Scientific has licensed rights to gene editing technology for bioproduction applications that it claims targets DNA more precisely and reliably than current approaches.
SAFC (Sigma-Aldrich Corporation) says it will invest across its life science businesses following a first quarter that saw “weak” contract manufacturing but flourishing viral and cell media sectors.
Cobra Biologics is looking for more scientists with plasmid production skills after BioCancell became the fifth firm in a year to ask the CMO to manufacture a DNA-based gene therapy candidate.
Biotech company Haplogen and the Center for Molecular Medicine of the Austrian Academy of Sciences this week released the largest collection of human cell lines that are deficient for single genes.
Tissue-based delivery tech developer Medgenics is in talks with Baxter Healthcare about new deal, but says continued focus on Factor VIII is not ‘mission critical’ to biopump platform.
Cell Biosciences plans to gain ground in the protein-based drugs market by acquiring Convergent Bioscience at the end of October for a cash sum of $12m (€8.6m.)
Bayer Healthcare is to deploy a new technique, developed by
Millipore, for genetically engineering cells to produce
pharmaceutically useful proteins that could both increase the yield
and accelerate drug production.
A new laboratory method for distinguishing pathogens from harmless
relatives has been developed by scientists in the US. The
high-throughput technique will enable the quick identification of
pathogens, which could be used for bioterror...
Invitrogen has created three new business divisions in a move to
strengthen its position in the growing biotechnology industry and
drive growth through improving links between its product
development cycle and customer base.
US scientists have shown that microRNA (miRNA) plays an essential
role in the development of the fruit fly. The discovery means that
miRNA could emerge as a new target for interventions aimed at
treating disease, or as a therapeutic...
Hamilton Life Science Robotics has taken Invitrogen's Gateway
Technology one step further by creating an automated cloning system
that monitors and tracks each plate undergoing various processes.
The system aims to further refine...
